Clinical Trial Update: Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients [Phase 3]

View source ↗

Summary

A Phase 3 trial in kidney transplant recipients compared conversion to sirolimus versus continued use of calcineurin inhibitors; the study has completed and res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Calcineurin inhibitor (CNIs)
• Rapamune (sirolimus)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Renal Transplantation | Phase 3 | Status: COMPLETED | Results posted: 2010-05-14